LOS ANGELES–(BUSINESS WIRE)–#celltherapy–DeciBio Consulting LLC’s latest market report, “Cell Therapy Manufacturing Global Market Report, First Edition: 2023-2028,” states that the global cell therapy manufacturing market, driven by innovation in manufacturing tools and the number of expected approvals in the near-term, is predicted to reach $14.5B by 2028.
The first edition of DeciBio’s cell therapy manufacturing (CTM) report takes a comprehensive look at the global CTM products and services market landscape, summarizing both present and future (2023-2028) use. Informed by a combination of primary research, secondary research, and proprietary DeciBio databases and tools, this report provides a quantitative and qualitative assessment of key segments (e.g., by customer type, products and services, stage of development, therapeutic area, cell type, manufacturing method, and geography). In addition, this report details market drivers (e.g., increased automation of manufacturing platforms), moderators (e.g., high manufacturing costs), trends (e.g., interest in the development and commercialization of allogeneic cell therapies), and profiles of top players in the space.
The CTM process is highly complex and can vary greatly based on the type of cell therapy being developed. A variety of technologies are utilized across the manufacturing workflow, from cell isolation to genetic modification, cell expansion, fill-finish, and cryopreservation. The number of tools available to support cell therapy development has increased in recent years, from the variety of cytokines on-market to the number of end-to-end manufacturing platforms, though limitations in the time- and cost-efficiency of manufacturing remain. As the field continues to expand beyond autologous CAR-T cell therapies to novel cell types and allogeneic manufacturing methods, the technologies supporting cell therapy development will continue to evolve.
|
Report Details |
|
|
Research Methods |
|
|
2028 Market Size |
$14.5 billion |
|
CAGR (2023-2028) |
21% |
|
Base Year |
2023 |
|
Forecast Period |
2023-2028 |
|
Market / Forecast Currency |
USD |
|
Report Coverage |
Market size, segmentation, and forecast; key market players and trends; assays and technologies; market drivers and moderators; competitive analysis |
|
Segments Covered |
|
Learn more about DeciBio’s Cell Therapy Manufacturing Global Market Report, First Edition: 2023-2028: www.decibio.com/product/global-cell-therapy-manufacturing-market-report-first-edition-2023-2028
Companies Profiled in the Report:
- Bio-Techne
- Catalent
- Charles River
- Corning
- Creative Bioarray
- Cytiva
- Fujifilm Diosynth Biotechnologies
- Lonza
- Maxcyte
- Millipore Sigma
- Miltenyi Biotec
- Revvity
- Samsung Biologics
- Sartorius
- STEMCELL Technologies
- ThermoFisher
- Wilson Wolf
- WuXi Apptec
Cell Therapy Manufacturing – Market Analysis:
Market Drivers
The recent success of cell therapies is driving interest in optimization of the manufacturing process, to enable the development of therapeutics with better efficacy and more advanced features. In response to this interest, a wave of innovation occurred in the tools supporting CTM, such as greater incorporation of automated systems and the development of end-to-end manufacturing platforms. Large pharmaceutical companies, have driven a significant portion of the market to-date, though small pharma companies will play an increasingly larger role as their products move successfully through clinical trials. The increasing success of allogeneic cell products and interest in non-viral engineering methods will spur additional market growth.
Market Moderators
Though the market is poised for rapid growth, barriers persist that may moderate how quickly the market grows. One of the greatest barriers faced today is the high manufacturing costs associated with cell therapy production. Although automation and improved manufacturing methods aim to address the high COGS, commercial implementation of these methods will require years of clinical validation before a reduction in cost is realized. In addition, a lack of manufacturing capacity and cell-type specific experience limits the ability of CDMOs / CROs to meet market demands, consequently slowing product development. Lastly, the biopharma industry faces a shortage of trained professionals experienced with CTM’s highly specialized procedures, which places a burden on biopharma to invest in training and retaining staff.
About DeciBio:
DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating innovation in precision medicine.
Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.
Contacts
Rebecca Burnham
Rebecca.burnham@decibio.com
310.451.4510